Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio molecular de la interfaz materno-fetal en la preeclampsia. (PREMAFE)

3 de noviembre de 2026 actualizado por: Carlos Simon Foundation

Estudio molecular de la interfaz materno-fetal de forma prospectiva hasta la aparición de preeclampsia mediante tecnología unicelular.

Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening consequences are needed. Thus, the detection of women at risk of suffering PE is key to apply preventive and treatment strategies. Recently, the maternal contribution to PE based on defective decidualization that prevents the establishment of a functional maternal-fetal interface has been evidenced. The main objective of this study is to identify molecular markers or aberrant maternal-fetal cell types that can be detected early in the development of the disease in maternal-fetal interface tissue (chorionic villi + decidua) collected during gestational weeks 9 to 15. Maternal-fetal interface biopsy will be collected from women who have a recommendation for aneuploidy testing. The remaining fragment will be used for this study.

Descripción general del estudio

Descripción detallada

The hypothesis is that those women who develop PE have impaired decidualization associated with shallow cytotrophoblast invasion during the development of the maternal-fetal interface whose molecular profile analysis at the single cell level will allow characterization of PE development prior to the onset of symptoms.

The purposed study is a biomedical, prospective, multicentre, case-control aimed to characterize the molecular profile of the maternal-fetal interface in the first trimester of pregnancy early in the development of preeclampsia using single-cell sequencing technology. Distinguishing the maternal and fetal origin of the chorionic biopsy cells, describing the maternal-fetal interface and deciphering the intercellular communications and altered pathways in PE and other obstetric complications could be suggested as a secondary outcome, as well as the characterization of the blood sample, the epigenome and metabolome of single cells or the validation of markers of the different cell types. Another objective will be to perform a molecular characterization of maternal-fetal blood and tissue samples collected at the time of delivery, with the aim of correlating the alterations detected in the first trimester with the molecular profiles at the end of pregnancy in both PE patients and controls.

Subjects will be 2084 pregnant women over the age of 18 recruited between 9 and 15 gestational weeks. Patients attending the participating referral centers for a chorionic villus biopsy due to the detection of a foetal chromosomal abnormality risk will provide the leftover chorionic biopsy sample after determination of the risk of trisomies and a peripheral blood sample for genotyping of maternal lymphocytes and circulating cRNA.

Data will be registered in an electronic Case Report Form (eCRF) specifically designed for this study. Monitoring activities and data verification will be performed during the whole study to ensure data quality, integrity and transparency.

The total estimated duration of the study is 52 months, of which the first 48 months will correspond to the recruitment period of the participants.

Tipo de estudio

De observación

Inscripción (Estimado)

2084

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Carlos Simón, MD, PhD

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Alicante
      • Alicante, Alicante, España
        • Reclutamiento
        • Hospital General Universitario Dr. Balmis
        • Contacto:
    • Murcia
      • Murcia, Murcia, España
        • Reclutamiento
        • Hospital Clinico Universitario Virgen de la Arrixaca
        • Contacto:
    • Santa Cruz de Tenerife
      • Santa Cruz de Tenerife, Santa Cruz de Tenerife, España
        • Reclutamiento
        • Hospital Universitario de Canarias
        • Contacto:
        • Sub-Investigador:
          • Walter Plasencia Acevedo
    • Valencia
      • Valencia, Valencia, España
        • Reclutamiento
        • Hospital Universitario y Politécnico La Fe
        • Contacto:
          • Rogelio Monfort Ortiz
          • Número de teléfono: +34 961 24 40 00
          • Correo electrónico: monfort_isaort@gva.es
        • Contacto:
          • Beatriz Marcos Puig
          • Número de teléfono: +34 961 24 40 00
          • Correo electrónico: marcos_bea@gva.es

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

N/A

Géneros elegibles para el estudio

Femenino

Método de muestreo

Muestra no probabilística

Población de estudio

The study population will consist of women aged 18 years or older with singleton pregnancies who, depending on their stage of pregnancy and willingness to participate, may be enrolled in one or both phases of the study:

  • Phase 1 (first trimester): Women attending the participating referral centers between 9 and 15 weeks of gestation to undergo chorionic villus sampling (CVS), either due to an increased risk of fetal chromosomal abnormalities identified through non-invasive prenatal screening or for any other medical indication. In these cases, participants will be asked to donate surplus chorionic villus tissue obtained during the diagnostic procedure, as well as a peripheral blood sample.
  • Phase 2 (delivery): Women who, regardless of whether they participated in the initial phase of the study, agree to donate placental tissue and maternal blood samples at the time of delivery. Participation in this phase may be offered at later stages of pregnancy.

Descripción

Inclusion Criteria:

  • Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved.
  • Women over the age of 18 at the time of signing the informed consent form.
  • Women who meet at least one of the following criteria at the time of inclusion:

Phase 1 (first trimester): Pregnant women between 9 and 15 weeks of gestation who are scheduled to undergo chorionic villus sampling (CVS) as part of the center's routine clinical practice.

Phase 2 (delivery): Women with an ongoing pregnancy, regardless of gestational age and without the requirement of having participated in Phase 1, who are willing to donate placental and maternal blood samples following delivery.

Exclusion Criteria:

  • Women with multiple pregnancy.
  • Non-evolving pregnancies (including delayed abortion/foetal orbit).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_CONTROL
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Cases group (phase 1)

Women recruited between 9 and 15 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy.

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.

Maternal-fetal interface tissue (placenta) and peripheral blood will be collected from women who develop preeclampsia or other obstetric complication at the end of their pregnancy. Clinical data will be compiled.

Control group (phase 1)

Women recruited between 9 and 15 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.

Maternal-fetal interface tissue (placenta) and peripheral blood will be collected from women who do not experience any complications or who do not experience the specific obstetric complication defined in the case group to which they are compared.

Cases group (phase 2)

Women recruited at delivery with preeclampsia or other complication.

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.

Maternal-fetal interface tissue (placenta) and peripheral blood will be collected from women who develop preeclampsia or other obstetric complication at the end of their pregnancy. Clinical data will be compiled.

Control group (phase 2)

Women recruited at delivery with no obstetric complication or who do not experience the specific obstetric complication defined in the case group to which they are compared.

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.

Maternal-fetal interface tissue (placenta) and peripheral blood will be collected from women who do not experience any complications or who do not experience the specific obstetric complication defined in the case group to which they are compared.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To charactize the molecular profile of the maternal-fetal interface (chorionic billi and decidua) between 9 and 15 weeks of gestation in healthy and preeclamptic pregnancies
Periodo de tiempo: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Differentially expressed genes between control vs preeclampsia group at the level of cell types/subtypes

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To characterise the molecular profile of the maternal-fetal interface between 9 and 15 weeks of gestation in pregnancies diagnosed with pregnancy complication other than preeclampsia
Periodo de tiempo: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Differentially expressed genes between control vs cases group at the level of cell types/subtypes.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
To characterise the epigenome and metabolome of individual cells from the maternal-fetal interface in healthy pregnancies and those diagnosed with preeclampsia or other pregnancy complication
Periodo de tiempo: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Differentially methylation profiles and differentially metabolites between control vs cases group at the level of cell types/subtypes.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
The discovery and validation of molecular markers as candidates for early diagnosis and/or therapy
Periodo de tiempo: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Area Under the ROC Curve and/or cell type phenotyping in in vitro cultures after disrupting the candidate

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
To characterize the molecular profile of the maternal-fetal interface (placenta) at the end of pregnancy in healthy and preeclamptic pregnancies
Periodo de tiempo: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Differentially expressed genes between control vs preeclampsia group at the level of cell types/subtypes

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Tamara Garrido, PhD, Fundación Carlos Simon para la investigación en salud de la mujer

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de noviembre de 2023

Finalización primaria (Estimado)

1 de diciembre de 2027

Finalización del estudio (Estimado)

1 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

22 de enero de 2024

Primero enviado que cumplió con los criterios de control de calidad

22 de enero de 2024

Publicado por primera vez (Actual)

31 de enero de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir